B2i Digital adds Precipio as featured company

By AI, Created 5:03 PM UTC, May 18, 2026, /AGP/ – B2i Digital named Precipio, a cancer diagnostics biotechnology company, as a Featured Company on May 11, 2026. The partnership highlights Precipio’s lab-based model, which combines pathology services and proprietary diagnostic products as the company pushes growth and margin improvement.

Why it matters: - Precipio’s model links clinical testing with product development, which can speed validation and commercialization of new cancer diagnostics. - The company is targeting hematologic malignancies, a high-stakes area where faster and more accurate diagnosis can affect treatment decisions. - B2i Digital’s Featured Company program gives Precipio visibility to investors as the company scales a commercial business.

What happened: - B2i Digital named Precipio, Inc. a B2i Digital Featured Company on May 11, 2026. - Precipio is a healthcare biotechnology company focused on cancer diagnostics for laboratories. - The company’s current focus is hematologic malignancies. - Precipio’s featured company profile is available here.

The details: - Precipio operates two integrated businesses: a Pathology Services business and a Products business. - The Pathology Services business provides specialized cancer diagnostic testing from CLIA-certified facilities in New Haven, Connecticut, and Omaha, Nebraska. - The Products business is built around proprietary assays including the HemeScreen and Bloodhound molecular platforms. - The clinical lab functions as a revenue-generating division and as a platform for the product R&D team. - Precipio says that structure allows faster and more cost-efficient development of new products. - The company says the model supports product development and validation, helps bring new diagnostic products to market, and supports gross-margin improvement and positive operating cash flow. - Ilan Danieli said Precipio is scaling a commercial business that grew net sales 30% last year. - Danieli also said the company is expanding gross margins and growing its Products business while continuing to generate positive operating cash flow. - Precipio says its mission is to address cancer misdiagnoses by developing diagnostic products and services. - The company says its products and services are designed to improve accuracy, laboratory workflow, patient outcomes, and healthcare expenses. - Precipio says it develops technologies in its laboratory, where the company designs, tests, validates, and uses the products clinically. - The company then commercializes those technologies as proprietary products for the global laboratory community.

Between the lines: - The announcement underscores why lab-enabled diagnostics companies can appeal to investors: they can combine recurring services revenue with product IP development. - B2i Digital’s endorsement is also a marketing and awareness push, not an independent investment rating. - The company’s disclosure says B2i Digital was compensated for investor awareness services tied to Precipio.

What’s next: - Precipio said it expects to continue scaling its commercial business and communicating its current positioning and value proposition through the B2i Digital program. - The company directs investors and other stakeholders to its website, SEC filings, investor materials, press releases, and social channels for ongoing updates, including Precipio’s website. - Precipio also says it posts material information on its website, X, and LinkedIn. - Investors can contact Precipio at investors@precipiodx.com or +1-203-787-7888 Ext. 523.

The bottom line: - Precipio is using a two-part diagnostics model to pair lab services with product development, and B2i Digital is giving the company a broader investor spotlight as it pursues growth and margin expansion.